| Autor: |
Porrata, L. F., Gertz, M. A., Geyer, S. M., Litzow, M. R., Gastineau, D. A., Moore, S. B., Pineda, A. A., Bundy, K. L., Padley, D. J., Persky, D., Lacy, M. Q., Dispenzieri, A., Snow, D. S., Markovic, S. N. |
| Předmět: |
|
| Zdroj: |
Leukemia (08876924); Jun2004, Vol. 18 Issue 6, p1085-1092, 8p |
| Abstrakt: |
Absolute lymphocyte count at day 15 (ALC-15) after autologous peripheral blood hematopoietic stem cell transplantation (APHSCT) is an independent prognostic factor for survival in multiple myeloma (MM); however, factors affecting ALC-15 in MM remain unknown. We hypothesized that the dose of infused peripheral blood autograft lymphocytes (autograft absolute lymphocyte count: A-ALC) impacts ALC-15 recovery. Between 1989 and 2001, 267 consecutive MM patients underwent APHSCT. We set out to determine the correlation between A-ALC and ALC-15 and the utility of A-ALC as a marker for ALC-15 recovery. A-ALC was found to be both a strong predictor for area under curve (AUC=0.93; P=0.0001) and strongly correlated with (rs=0.83; P=0.0001) ALC-15 recovery. Higher infused A-ALC was significantly correlated with an ALC-15?500/µl. In addition, median post-transplant overall survival (OS) and time to progression (TTP) were longer in patients who received an A-ALC?0.5 × 109 lymphocytes/kg versus A-ALC <0.5 × 109 lymphocytes/kg (58 vs 30 months, P=0.00022; 22 vs 15 months, P<0.00012, respectively). Multivariate analysis demonstrated A-ALC as an independent prognostic indicator for OS and TTP. These results indicate that an infused dose of autograft lymphocytes significantly impacts clinical outcome post-APHSCT in MM.Leukemia (2004) 18, 1085-1092. doi:10.1038/sj.leu.2403341 Published online 25 March 2004 [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
